Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 13:12:11631-11638.
doi: 10.2147/CMAR.S280141. eCollection 2020.

Is There a Survival Benefit for Patients with Advanced Ovarian Clear Cell Carcinoma Who Complete More Than 6 Cycles of Postoperative Chemotherapy?

Jing Wang #  1   2   3   4 , Yuying Shi #  1   3   4 , Yan Liu  2 , Wei Li  5 , Hong Jiang  2 , Hongbing Cai  1   3   4
Affiliations

Is There a Survival Benefit for Patients with Advanced Ovarian Clear Cell Carcinoma Who Complete More Than 6 Cycles of Postoperative Chemotherapy?

Jing Wang et al. Cancer Manag Res. .

Abstract

Purpose: To provide a reference for clinicians, whether patients with advanced ovarian clear cell carcinoma (OCCC) require chemotherapy (CT) for more than 6 cycles after tumor debulking.

Patients and methods: A retrospective review was performed on 85 women diagnosed and treated for advanced OCCC. Outcomes of patients who underwent >6 vs ≤6 cycles of CT were analyzed based on clinicopathological factors.

Results: Among the 85 patients with advanced OCCC, 47 patients underwent ≤6 cycles of CT, and 38 patients underwent CT for over 6 cycles. Out of these, 49 patients had disease recurrence, and 35 died. The 2-year progression-free survival (PFS) for patients in the two groups was 51.5% and 42.2% (P＞0.05), respectively. The 2-year overall survival (OS) was 59.7% and 64.5%, respectively (P＞0.05), and the difference was not statistically significant. Multivariate analysis showed that residual tumor diameter was an independent risk factor for prognosis (PFS and OS). We divided the patients into three groups according to residual tumor diameter as 0 (R0), ≤1cm (R1), and >1cm (R2). The prognosis of R0 was better than R1 and R2. Further studies found that patients who received postoperative adjuvant chemotherapy for over 6 cycles showed no difference in improved prognosis, regardless of residual tumor diameter.

Conclusion: Patients with advanced OCCC who received more than 6 courses of adjuvant chemotherapy after surgery did not show improved prognosis. The residual tumor diameter is an independent indicator of prognosis in patients with advanced OCCC. Complete staging improves the prognosis of patients compared to the ideal or non-ideal cytoreductive surgery.

Keywords: chemotherapy; ovarian clear cell carcinoma; overall survival; prognosis; residual tumor.

PubMed Disclaimer

Conflict of interest statement

The authors report no competing financial interests or conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow chart of research object selection.
Figure 2
Figure 2
Effects of different chemotherapy cycles on PFS (P > 0.05).
Figure 3
Figure 3
Effects of different chemotherapy cycles on OS (P > 0.05).
Figure 4
Figure 4
According to the diameter of residual tumor, the patients were divided into three subgroups, and the effects of chemotherapy cycle on OS were compared (P > 0.05).
Figure 5
Figure 5
According to the diameter of residual tumor, the patients were divided into three subgroups, and the effects of chemotherapy cycle on PFS were compared (P > 0.05).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Machida H, Matsuo K, Yamagami W, et al. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study. Gynecol Oncol. 2019;153:589–596. doi:10.1016/j.ygyno.2019.03.243 - DOI - PMC - PubMed
    1. Kim SI, Lee JW, Lee M, et al. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. Gynecol Oncol. 2018;148:375–382. doi:10.1016/j.ygyno.2017.12.005 - DOI - PubMed
    1. Sugiyama T, Okamoto A, Enomoto T, et al. Randomized Phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trial. J Clin Oncol. 2016;34:2881–2887. doi:10.1200/JCO.2016.66.9010 - DOI - PubMed
    1. Schnack TH, Høgdall E, Nedergaard L, Høgdall C. Demographic clinical and prognostic factors of primary ovarian adenocarcinomas of serous and clear cell histology-a comparative study. Int J Gynecol Cancer. 2016;26:82–90. doi:10.1097/IGC.0000000000000585 - DOI - PubMed
    1. Köbel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203–211. doi:10.1097/PGP.0b013e3181c042b6 - DOI - PubMed